+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID07027124

Evaluation of Neoadjuvant Androgen Deprivation Therapy, Darolutamide, and Pembrolizumab Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-10-07

40

Participants Needed

1

Research Sites

178 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination therapy involving Androgen Deprivation Therapy ADT, Darolutamide, and Pembrolizumab in men with high-risk non-metastatic prostate cancer. This phase II study focuses on patients whose cancer is molecularly stratified by specific genomic characteristics, aiming to reduce disease burden before and after surgery. The goal is to see if this neoadjuvant and adjuvant treatment approach leads to minimal residual disease in this high-risk group. Participants will receive a combination of treatments before undergoing radical prostatectomy. This includes ADT with Leuprolide injections every 12 weeks, Darolutamide tablets taken twice daily for 16 weeks, and Pembrolizumab infusions every three weeks for five cycles. After surgery, patients will continue Pembrolizumab infusions every three weeks for 12 additional cycles. This treatment plan spans pre-surgery neoadjuvant therapy and post-surgery adjuvant therapy phases. Throughout the study, participants will be closely monitored with various assessments including tumor volume measurements, immunological blood tests, and genetic sequencing over several months. Researchers will evaluate the presence of minimal residual disease at surgery, pathological response, tumor downstaging, and track safety through adverse event reports. Long-term outcomes such as progression-free and metastasis-free survival will also be followed for up to five years, ensuring comprehensive evaluation of treatment effects and safety.

CONDITIONS

Brief Title

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Research Team

D

Daniela Delbeau- Zagelbaum, RN, NP

M

Monali Fatterpekar, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here